Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
暂无分享,去创建一个
C. Porsbjerg | G. Canonica | P. Kuna | R. Djukanović | A. Bossios | E. Bel | S. Korn | B. Dahlén | E. Zervas | F. Mihălțan | K. Biekšienė | A. Frix | R. Louis | A. Bourdin | B. Gemicioğlu | L. Heaney | A. ten Brinke | L. Lehtimäki | D. Ramos-Barbón | S. Škrgat | Z. Lazic | S. Sergejeva | S. Popović-Grle | V. Sedlák | N. Nenasheva | I. Grisle | Z. Csoma | Dóra Lúðvíksdóttir | Joerg Leuppi | Marcus Butler | Cláudia Chaves Loureiro | C. Chaves Loureiro | D. Lúðvíksdóttir | Joerg D Leuppi | J. Leuppi
[1] C. Galeone,et al. Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life , 2022, Journal of asthma and allergy.
[2] G. Koppelman,et al. Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.
[3] Todor A Popov,et al. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. , 2022, The journal of allergy and clinical immunology. In practice.
[4] C. Porsbjerg,et al. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study , 2022, Journal of asthma and allergy.
[5] G. E. Carpagnano,et al. Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy , 2021, Biomedicines.
[6] M. K. Ruddy,et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. , 2021, The New England journal of medicine.
[7] I. Pavord,et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. , 2021, The Lancet. Respiratory medicine.
[8] L. Renaud,et al. Anti-IL5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry. , 2021, The journal of allergy and clinical immunology. In practice.
[9] C. Porsbjerg,et al. The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma , 2021, Airway pharmacology and treatment.
[10] J. Upham,et al. Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.
[11] K. Kuwano,et al. Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study , 2021, Journal of asthma and allergy.
[12] G. Canonica,et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis , 2021, Allergy.
[13] J. Stone,et al. Quantification of Glucocorticoid-associated morbidity in Severe Asthma using the Glucocorticoid Toxicity Index. , 2020, The journal of allergy and clinical immunology. In practice.
[14] O. Resta,et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy , 2020, Therapeutic advances in respiratory disease.
[15] A. Frix,et al. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. , 2020, Biochemical pharmacology.
[16] R. Louis,et al. Real‐world experience with mepolizumab: Does it deliver what it has promised? , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[17] C. Porsbjerg,et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries , 2019, European Respiratory Journal.
[18] G. Ortega,et al. Combination Biologic Therapy for Severe Persistent Asthma. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[19] L. Calzetta,et al. Monoclonal antibodies in severe asthma: is it worth it? , 2019, Expert opinion on drug metabolism & toxicology.
[20] G. Canonica,et al. The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research , 2018, European Respiratory Journal.
[21] Rejmon Dedaj,et al. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.
[22] K. Rabe,et al. Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.
[23] Richard Beasley,et al. After asthma: redefining airways diseases , 2017, The Lancet.
[24] E. Israel,et al. Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.
[25] K. Rabe,et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.
[26] I. Pavord,et al. Severe eosinophilic asthma: a roadmap to consensus , 2017, European Respiratory Journal.
[27] A. Zwinderman,et al. The prevalence of severe refractory asthma. , 2015, The Journal of allergy and clinical immunology.
[28] I. Pavord,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.
[29] E. Bleecker,et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.